Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: additional evidence
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Updated Patient Access Scheme (PAS) submission from Forest Laboratories UK
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Economic analysis of updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR)
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Summary of non-inferiority analysis in updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR)
This page was last updated: 23 January 2013